John Depalma, DO
Nephrology · Brick, NJNPI 1407054471
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 309 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 30.8% of the total.
Across 309 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Vifor Pharma, Inc.$817
- Bayer$380
- Amgen$352
- Otsuka America Pharmaceutical, Inc.$235
- OPKO Pharmaceuticals, LLC$226
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,14995%
- Education$3555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 85 | $2,006 |
| Vifor Pharma, Inc. | 49 | $817 |
| Bayer | 22 | $380 |
| Amgen(2 entities) | 25 | $352 |
| Otsuka America Pharmaceutical, Inc. | 14 | $235 |
| OPKO Pharmaceuticals, LLC | 8 | $226 |
| Aurinia Pharma U.S., Inc. | 6 | $221 |
| W. L. Gore & Associates, Inc. | 2 | $215 |
| GSK | 13 | $208 |
| Travere Therapeutics, Inc. | 15 | $201 |
| Ardelyx, Inc. | 10 | $163 |
| Davol Inc. | 1 | $140 |
| Novo Nordisk | 7 | $139 |
| Mallinckrodt Enterprises LLC | 4 | $134 |
| Mallinckrodt Hospital Products Inc. | 3 | $131 |
| Johnson & Johnson | 2 | $130 |
| Infobionic, Inc | 1 | $99 |
| Daiichi Sankyo Inc. | 6 | $93 |
| Akebia Therapeutics Inc | 6 | $91 |
| Boston Scientific | 1 | $88 |
| Calliditas Therapeutics US Inc. | 4 | $61 |
| Fresenius USA Marketing, Inc. | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Lundbeck LLC | 4 | $53 |
| Shire North American Group Inc | 3 | $38 |
| Bard Peripheral Vascular, Inc. | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $24 |
| Amarin Pharma, Inc. | 2 | $24 |
| Nxstage Medical, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $18 |
| Novartis | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,504 in reported general payments places this provider in the 85th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 24 | $1,111,340 |
| FarxigaDapagliflozin Propanediol | 128 | $172,382 |
| XphozahTenapanor Hcl | 32 | $143,330 |
| Droxidopa | 12 | $122,363 |
| LokelmaSodium Zirconium Cyclosilicate | 54 | $65,863 |
| KerendiaFinerenone | 57 | $64,051 |
| Tolvaptan | 12 | $41,968 |
| OzempicSemaglutide | 32 | $37,787 |
| JardianceEmpagliflozin | 33 | $36,167 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $33,601 |
| MounjaroTirzepatide | 31 | $32,006 |
| RayaldeeCalcifediol | 19 | $28,643 |
| JanuviaSitagliptin Phosphate | 14 | $9,636 |
| Cinacalcet Hcl | 37 | $8,565 |
| Sevelamer Carbonate | 29 | $6,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $59 | $1,111,34024 claims |
| AstraZenecaFarxiga, Lokelma | $2,006 | $238,246182 claims |
| BayerKerendia | $380 | $64,05157 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $24 | $41,96812 claims |
| Novo NordiskOzempic | $139 | $37,78732 claims |
| Boehringer IngelheimJardiance | $18 | $36,16733 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $226 | $28,64319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Brick
- Joseph AlbaneseBrick$41K
- Robert BrunoBrick$9K
- Winicjusz PaleckiBrick$8K
- Angelo MarkatosBrick$6K
- Rajat KapoorBrick$6K
- Daniel BrouderBrick$5K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.